Patient ID	Patient Name		Birth Date	Gender	Age
SA00144159	SAMPLEREPORT, TESTINGPATIENT		1987-12-28	F	33
Order Number	**Client Order Number**	**Ordering Physician**	**Report Notes**		
SA00144159	SA00144159	CLIENT,CLIENT			
Account Information		**Collected**			
C7028846 DLMP Rochester		14 Apr 2021 00:00			

Chromogenic FVIII Inhibitor Profile

Chromogenic FVIII Inhibitor Interp

MCR

IMPRESSION: No evidence of factor VIII inhibitor.

COMMENTS: Decreased baseline chromogenic factor VIII coagulant activity (FVIII). The FVIII inhibitor titering assay (Bethesda), performed after the pre-analytical heat-inactivation of patient plasma and using bovine reagent based chromogenic FVIII reagents, demonstrates no evidence of a specific inhibitor of coagulation factor VIII. The Bethesda titer is <0.5 Bethesda Units .

Reviewed by

MCR

KATHLEEN MEYERS

Result Name	Value	Unit	Reference Value	Performing Site
Chromogenic FVIII, P	56.0	%	55.0–200.0	MCR
Assay discrepancy between chromogenic FVIII assay and one stage FVIII assay may potentially result in a missed diagnosis (or misclassification of severity) of mild/moderate hemophilia A. Serum and plasma specimens, either collected in EDTA or contaminated with heparin, will falsely lower FVIII levels.				
Chromogenic FVIII Inhibitor Titer,P	<0.5	BU	≤0.5	[1] MCR

Received: 14 Apr 2021 13:12

Reported: 14 Apr 2021 13:21

Laboratory Notes

[1] This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292